
























CRUK CENTRE FOR DRUG DEVELOPMENT

BIOLOGICAL THERAPIES

AGENT/TRIAL	TARGET/TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE					
					PROJECT INITIATION	EXPLORATORY	PRE-CLINICAL	TRIAL SET UP	PHASE I	PHASE II
DETERMINE - Agent tbc	ADC target tbc		Rare adult cancers	Phase II▶					
CY101	Peptide β-catenin, WNT		Adenocortical carcinoma	First in class▶					
KJ103	Antibody TROP2		Solid	First in class▶					
NVG222 solid	BITE ROR1, CD3		Solid	First in indication▶					
ALETA001	Protein CD19, CD20		Lymphoma	First in class▶					
HMBD001	Antibody Her3		Solid, prostate	First in human (closed)▶					
NVG222 haematological	BITE ROR1, CD3		Lymphoma	First in human▶					
VTP600 (MAGE)	Vaccine MAGE3, NY-ESO-1		Lung	First in human (closed)▶					
UCB4594	Antibody HLA-G1		Solid, renal	First in human▶					
DETERMINE - Atezolizumab - Trastuzumab/ Pertuzumab	Antibodies PDL1 HER2		Rare adult, paediatric & TYA cancers	Phase II Phase II combination▶▶				
Ginisortamab (UCB6114)	Antibody Gremlin1		Pancreatic	First in class Phase II▶					

CRUK CENTRE FOR DRUG DEVELOPMENT

SMALL MOLECULE THERAPIES

AGENT/TRIAL	TARGET/TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE						
					PROJECT INITIATION	EXPLORATORY	PRE-CLINICAL	TRIAL SET UP	PHASE I	PHASE II	
DETERMINE - Agent tbc	Target tbc	 The University of Manchester 	Rare adult, paediatric & TYA cancers	Phase II	→						
BT1718	MT1-MMP		Solid, lung	First in class (closed)	→	→	→	→	→	→	
HTL0039732	EP4		Solid, colorectal, prostate, gastric, oesophageal, renal	First in human	→	→	→	→	→	→	
LY3143921	Cdc7		Solid, colorectal, ovarian, lung	First in human (closed)	→	→	→	→	→	→	
TT702 (CURATE)	adenosine A _{2B} R		Solid	First in human	→	→	→	→	→	→	
DETERMINE - Alectinib - Dabrafenib/ Trametinib - Entrectinib	ALK, BRAF, MEK, ROS1, TKI, TRK	 The University of Manchester  	Rare adult, paediatric & TYA cancers	Phase II Phase II combination Phase II	→	→	→	→	→	→	→
DETERMINE - Capmatinib - Vemurafenib/ Cobimetinib	BRAF, cMET, HGFR, MAP, MEK	 The University of Manchester  	Rare adult cancers	Phase II Phase II combi (closed)	→	→	→	→	→	→	→